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The porcine reproductive and respiratory syndrome virus (PRRSV) is the cause of one 
of the most economically important diseases affecting swine worldwide. Efforts to 
develop a next-generation vaccine have largely focused on envelope glycoproteins to 
target virus-neutralizing antibody responses. However, these approaches have failed to 
demonstrate the necessary efficacy to progress toward market. T cells are crucial to the 
control of many viruses through cytolysis and cytokine secretion. Since control of PRRSV 
infection is not dependent on the development of neutralizing antibodies, it has been 
proposed that T cell-mediated immunity plays a key role. Therefore, we hypothesized 
that conserved T cell antigens represent prime candidates for the development a novel 
PRRS vaccine. Antigens were identified by screening a proteome-wide synthetic peptide 
library with T cells from cohorts of pigs rendered immune by experimental infections 
with a closely related (subtype 1) or divergent (subtype 3) PRRSV-1 strain. Dominant 
T cell IFN-γ responses were directed against the non-structural protein 5 (NSP5), and 
to a lesser extent, the matrix (M) protein. The majority of NSP5-specific CD8 T cells 
and M-specific CD4 T cells expressed a putative effector memory phenotype and were 
polyfunctional as assessed by coexpression of TNF-α and mobilization of the cytotoxic 
degranulation marker CD107a. Both antigens were generally well conserved among 
strains of both PRRSV genotypes. Thus, M and NSP5 represent attractive vaccine 
candidate T cell antigens, which should be evaluated further in the context of PRRSV 
vaccine development.
Keywords: porcine reproductive and respiratory syndrome virus, T cell, iFn-γ, antigen identification, phenotype 
and function, vaccine
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inTrODUcTiOn
Porcine reproductive and respiratory syndrome (PRRS) is one of 
the most important pig diseases worldwide with a huge economic 
impact, estimated in the USA alone to exceed $600 million annu-
ally (1). The PRRS virus (PRRSV) is an arterivirus, which exists 
in two distinct genotypes: 1 (formerly European) and 2 (formerly 
North American). Common to most RNA viruses, the PRRSV 
replication cycle is prone to mutation and recombination events 
resulting in rapid evolution. This characteristic is most dramati-
cally illustrated by the recent emergence of highly pathogenic 
variants in Southeast Asia and Eastern Europe (2–8). Efficacious 
control strategies that will address PRRSV variability are there-
fore urgently sought.
Vaccination is considered a key element to PRRS control, and 
both live attenuated and inactivated vaccines derived from the 
two PRRSV genotypes are licensed. Live attenuated vaccines are 
widely accepted to be the more efficacious and confer protec-
tion from disease following challenge with homologous PRRSV 
strains but offer variable levels of protection against heterologous 
strains (9). Vaccination with live vaccines can also result in 
long-lasting viremia and may be transmitted by viral shedding 
to unvaccinated pigs and transplacentally in pregnant sows lead-
ing to congenitally infected litters (10). The potential of vaccine 
strains to revert to virulence is a further safety concern, with 
vaccine-derived isolates shown to be pneumovirulent in experi-
mentally infected pigs (11) and linked to PRRS disease outbreaks 
in the field (12). Reversion to virulence has been described for 
live vaccines of both genotypes and may occur through either 
mutation or recombination events (13, 14). Inactivated PRRSV 
vaccines are safe but are of limited efficacy, affording little to 
no protection against heterologous challenge (15). To date, the 
majority of experimental subunit approaches have focused on the 
envelope glycoprotein, GP5, as this had long been considered the 
major target of neutralizing antibodies (nAbs). However, recom-
binant GP5 protein was poorly immunogenic, failed to provide 
protection, and even exacerbated disease upon challenge (16). 
Expression of GP5 using plasmid DNA or viral vectors, alone 
or in conjunction with other structural proteins, have shown 
variable immunogenicity and at best confer a limited degree of 
protection (17–21). The limitations of existing and experimental 
vaccines support the investigation of novel approaches to PRRSV 
vaccine development.
Porcine reproductive and respiratory syndrome virus infec-
tion is associated with immunomodulation of innate immune 
response, which negatively impacts induction of the adaptive 
immune responses required for effective virus control. While 
PRRSV-specific antibody responses are observed from 7 to 
10  days postinfection, nAb responses are often not observed 
until >4 weeks postinfection (22). Moreover, the level of nAbs 
when measurable is often far lower than those elicited by other 
viruses (23). Since animals may clear PRRSV infection and be 
immune to reinfection in the absence of nAbs, cell-mediated 
responses are thought to play an important role (5, 6, 23, 24). 
PRRSV infection results in virus-specific T cells detectable in the 
blood after 7–14 days, and we recently showed that a pathogenic 
PRRSV-1 subtype 3 strain induced a stronger IFN-γ response 
than conventional strains, which was associated with enhanced 
clearance of the virus (5). Few studies have conducted an in-depth 
analysis of the PRRSV-specific T cell response. While an early study 
found that CD4 T cells were necessary to drive PRRSV-specific 
proliferative responses in vitro (25), a more recent study indicated 
that CD8 T cells are the predominant population expanded by 
in vitro PRRSV stimulation (26). We have shown that both CD4 
and CD8 T cells contribute to PRRSV-specific IFN-γ responses 
(27). While IFN-γ is known to inhibit PRRSV replication at least 
in vitro (28, 29), cytotoxic killing of infected cells by CD8 T cells 
likely represents an important effector mechanism in vivo (30), 
and CD8 T cells are the dominant T cell population infiltrating 
the lungs during PRRSV infection (31). With regards to T cell 
specificity, we previously reported a range of IFN-γ reactivity to 
PRRSV-1 proteins, most notably to the M protein, as well as the 
viral polymerase, NSPs 1, 2, and 5, and GP5 (27), many of which 
had also been described by others to be T cell antigens (32–37).
Therefore, we hypothesize that conserved PRRSV antigens 
that are the targets of T cell responses represent prime candidates 
for the development of a novel PRRS vaccine. To address this, an 
attenuated subtype 1 and a pathogenic subtype 3 PRRSV-1 strain 
were used in an experimental infection and challenge model. T 
cell reactivity was monitored longitudinally and antigen reactiv-
ity assessed after each infection by screening of a proteome-wide 
synthetic PRRSV peptide library. Two antigens that were strongly 
recognized by both groups of animals were selected for detailed 
study. Flow cytometric analyses quantitatively and qualitatively 
defined the specificity, phenotype, and function of antigen-
specific T cells.
MaTerials anD MeThODs
Viruses
The PRRSV-1 subtype 1 MARC-145 cell attenuated Olot/91 
strain was kindly provided by Dr. Sonia Zúñiga and Prof. Luis 
Enjuanes, Centro Nacional de Biotecnología, Madrid, Spain, 
and propagated in MARC-145 cells (27). The virulent PRRSV-1 
subtype 3 strain SU1-Bel (isolated from material kindly provided 
by Dr. Tomasz Stadejek, Warsaw University of Life Sciences, 
Poland) and the PRRSV-1 subtype 1 strain 215-06 were both 
propagated in porcine alveolar macrophages [PAMs; Cell and 
Tissue Culture Unit, Animal and Plant Health Agency (APHA), 
Addlestone, UK] (5).
PrrsV-1 Peptides and Proteins
A synthetic overlapping peptide library of 1275 pentadecamer 
peptides off-set by four amino acids was synthesized (JPT Peptide 
Technologies, Berlin, Germany) using the predicted amino acid 
sequences of the structural proteins of PRRSV-1 Olot/91 strain 
(GenBank Accession No. X92942.1) and the non-structural pro-
teins of the closely related Lelystad strain (GenBank Accession 
No. AY588319.1) (27). Peptides were reconstituted and aliquots 
pooled to represent 19 proteins of PRRSV-1 as previously 
described (27). Antigenic M and NSP5 peptides were identified 
by screening peptides using a two-way matrix pooling system 
(38). Antigenic peptides with amino acid substitutions predicted 
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from analyses of additional PRRSV strains were synthesized (JPT 
Peptide Technologies).
experimental PrrsV infection of Pigs
All animal work was approved by the APHA Ethics Committee 
and conducted in accordance with the UK Animals (Scientific 
Procedures) Act 1986. An experimental infection and challenge 
study was carried out using 12-week-old, PCV-2 free, PRRSV 
antibody-negative Large White/Landrace cross-bred pigs. This 
experiment was designed to enable a comparison of T cell 
responses following primary infection to those boosted following 
secondary exposure. Animals were inoculated intranasally with 
106 TCID50 PRRSV-1 Olot/91 (n =  5) or 104 TCID50 PRRSV-1 
SU1-Bel (n = 5). Thirty-five days postinoculation, pigs were chal-
lenged with increased doses of the homologous virus, 107 TCID50 
PRRSV-1 Olot/91 and 105 TCID50 PRRSV-1 SU1-Bel. Animals 
were monitored for clinical scores and rectal temperatures and 
blood samples were collected at intervals from 2 days postinfec-
tion (dpi) until the end of the study, 60  dpi, as described (5). 
Serum samples were stored at −80°C for subsequent analysis 
and heparinized blood was used for isolation of peripheral blood 
mononuclear cells (PBMCs).
PrrsV Detection by Quantitative rT-Pcr
Standard PRRSV-1 nucleoprotein gene (ORF7) RNA was pre-
pared from Olot-91and SU1-Bel strains (5). RNA was isolated 
from serum using the QIAamp Viral RNA Mini Kit (Qiagen, 
Crawley, UK) and PRRSV RNA measured by quantitative real-
time reverse transcription PCR (qRT-PCR) using the QIAGEN 
QuantiTect® Probe RT-PCR kit (5).
Detection of PrrsV-neutralizing antibody 
responses
Porcine reproductive and respiratory syndrome virus nAb titers 
in serum samples were determined as described (6) with minor 
modifications. Serial twofold dilutions of heat-inactivated sera 
were incubated with 400 TCID50 of PRRSV for 1  h at 37°C. 
Neutralization of PRRSV-1 Olot/91 and SU1-Bel strains were 
assessed using MARC-145 cells (5  ×  103  cells/well) or PAMs 
(2 × 105 cells/well), respectively. After 72 h incubation, infection 
was assessed by IPX and antibody titers calculated as log2 of the 
reciprocal serum dilution that fully neutralized viral replication 
in 50% of the wells.
assessment of PrrsV-specific T cell 
responses in Peripheral Blood
Peripheral blood mononuclear cells were prepared from heparin 
blood as described and aliquots cryopreserved at a density of 
1–2 ×  107  cells/ml in 10% DMSO in FBS (39). Fresh or previ-
ously cryopreserved PBMC were suspended in cRPMI and IFN-γ 
responses to antigenic stimulation assessed by ELISpot assay (27) 
or flow cytometry (38). For IFN-γ ELISpot assay, 5 × 105 cells in 
100 μl were added to wells of a precoated and blocked ELISpot 
plate (96-well Multiscreen-IP Filter Plates; Millipore, Watford, 
UK) and for flow cytometry 1 ×  106  cells in 50 μl were added 
to wells of a 96-well round-bottom tissue culture plate (Costar, 
Fisher Scientific, Loughborough, UK). Cells were stimulated 
with an equal volume of PRRSV-1 at a multiplicity of infection 
MOI  =  0.1, or peptides at a final concentration of 1  μg/ml. 
Negative controls for peptide and virus stimulation were cells 
incubated in cRPMI alone or with mock-virus supernatants, 
respectively. For flow cytometry, PBMC were incubated at 37°C 
for 2 (peptide-stimulation) or 14–16 (virus-stimulation) hours 
and then Brefeldin A (GolgiPlug, BD Biosciences, Oxford, UK) 
was added at 1  μl/well and cells were further incubated for a 
further 16–18 or 6 h following stimulation with peptide or virus, 
respectively. In defined experiments to assess cytotoxic degranu-
lation, CD107a-FITC or IgG1 isotype control-FITC mAbs (both 
AbD Serotec, Oxford, UK; 10 μl/well) and Monensin (Golgi Stop, 
BD Biosciences; 0.67  μl/ml) were added in conjunction with 
Brefeldin A (38). After incubation, PBMC were surface stained 
with the following directly conjugated mAbs: CD4-PerCP-Cy5.5 
(clone 74-12-4, BD Biosciences), CD8α-PE (clone 76-2-11, BD 
Biosciences), and the Near Infra-Red Fixable Live/Dead Viability 
Dye (Life Technologies) or the Zombie Near Infra-Red Fixable 
Viability Kit (BioLegend, London, UK) (39). In defined experi-
ments, CD44-eFluor450 (clone IM7, eBioscience, Hatfield, UK) 
or one of the following mAbs conjugated to Alexa Fluor® 488 
using Zenon Mouse IgG Labeling Kits (Life Technologies): CD62L 
(clone CC32, AbD Serotec), CD27 (clone b30c7, kindly provided 
by Dr. Wilhelm Gerner, University of Veterinary Medicine, 
Vienna, Austria) (40), and CD25 (clone K231.3B2, AbD Serotec) 
were additionally included in the surface stain. Following fixa-
tion and permeabilization, PBMC were stained with IFN-γ-Alexa 
Fluor 647 (clone CC302, AbD Serotec) and TNF-α-Brilliant Violet 
421 (clone MAb11, Biolegend) or the respective isotype controls 
(Alexa Fluor 647 mouse IgG1 isotype control, AbD Serotec, and 
Brilliant Violet 421 mouse IgG1 isotype control, Biolegend) 
and analyzed using a MACSQuant Analyzer (Miltenyi Biotec, 
Bisley, UK) or a CyAn ADP flow cytometer (Beckman Coulter, 
High Wycombe, UK) (39). Live singlet CD4+CD8int (CD4) and 
CD4−CD8high (CD8) T cell populations (41) were gated upon and 
IFN-γ+ cells within these populations analyzed for coexpression 
of cell surface markers or TNF-α. Gates were set based on the 
corresponding isotype control and the number of singlet live lym-
phocytes acquired for analysis ranged from 200,000 to 400,000. In 
all instances, cell viability was confirmed to be >60%.
Mhc haplotype Determination by  
low-resolution Pcr-Based analysis
Pigs were genotyped for their swine leukocyte antigen (SLA) class 
I and II haplotypes by running low-resolution PCR-screening 
assays (PCR-SSP) on PBMC-derived genomic DNA as previously 
described (42).
sequence analysis of PrrsV
The predicted amino acid sequences of M (from 64 PRRSV-1 
and 31 PRRSV-2 strains) and NSP5 (from 19 PRRSV-1 and 36 
PRRSV-2 strains) proteins were aligned using the Clustal W algo-
rithm on MegAlign (DNAStar Lasergene 9 Core Suite, Madison, 
WI, USA). The PRRSV-1 strains jointly analyzed for all three 
T cell antigenic regions were as shown in Figure  6B, with the 
FigUre 1 | Outcome of infection and subsequent challenge infection with PrrsV-1 strains and association with virus-specific immune responses. 
Pigs were experimentally infected intranasally with either an attenuated PRRSV-1 strain (Olot/91; open symbols; n = 5) or a virulent sub-genotype 3 strain (SU1-Bel; 
closed symbols; n = 5) strains on day 0 and day 35 postinfection and PRRSV genome copy numbers in serum assessed (a). Serum neutralizing antibody titers 
(SNT) were assessed against PRRSV Olot/91 infectivity in vitro (B). IFN-γ expression by CD4+CD8αlow (CD4) and CD4−CD8αhigh (CD8) T cells was assessed by flow 
cytometry following mock (square symbols) or homologous virus (circle symbols) stimulation [(c,D) respectively]. Results are expressed as the mean data for each 
group, error bars represent the SEM. For RT-qPCR data and VNTs, values were compared to the corresponding value on 0 dpi whereas for T cell IFN-γ data from 
virus-stimulated cultures were compared against the corresponding mock stimulated culture for each time point using a two-way analysis of variance (ANOVA) 
followed by a Tukey’s multiple comparison test; ***p < 0.001, **p < 0.01.
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GenBank accession numbers shown. The consensus sequence of 
the identified T cell antigenic regions from the PRRSV-2 strains 
examined was determined from the ClustalW alignment.
statistical analysis
GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA, USA) 
was used for graphical and statistical analysis of data sets. A one-
way or two-way analysis of variance (ANOVA) was employed 
to analyze fixed effects on different traits with post hoc tests as 
detailed in the figure legends. A p-value <0.05 was considered 
statistically significant.
resUlTs
experimental infection and subsequent 
homologous challenge with PrrsV-1 
Olot/91 or sU1-Bel and association with 
neutralizing antibody and T cell iFn-γ 
responses
Groups of five pigs were inoculated intranasally with 106 TCID50 
of the attenuated PRRSV-1 subtype 1 strain Olot/91 or with a 
lower dose of 104 TCID50 of the divergent virulent subtype 3 
PRRSV strain with the aim of infecting animals but with a reduced 
likelihood of severe clinical disease. On day 35 postinfection, all 
animals were challenged by inoculation of the 10-fold higher dose 
of homologous virus than was used in the primary infection. As 
predicted, both groups showed mild clinical scores throughout 
the experiment, with the SU1-Bel group displaying several days 
(2 and 5–11  dpi) of elevated rectal temperatures following the 
primary inoculation (data not shown). Following the challenge 
at 35 dpi, there was no increase in clinical scores in the Olot/91 
group and only mild hyperthermia observed on 37 and 38 dpi in 
the SU1-Bel group (data not shown). Quantitative RT-PCR analy-
ses of serum samples showed a peak in PRRSV copy numbers in 
the Olot/91 group on 14 dpi (p < 0.01) that resolved completely by 
30 dpi (Figure 1A). Statistically significant PRRSV copy numbers 
were seen on 7 dpi in the SU1-Bel group (p < 0.01), but these were 
rapidly cleared by 14 dpi. There was also no detectable viral RNA 
upon challenge, which taken together with the clinical scores sug-
gests that the initial infection afforded a high degree of protection 
against reinfection.
In the PRRSV-1 Olot/91 infected group, Olot/91 neutralizing 
Abs were detectable from 14 dpi and levels steadily increased to 
a statistically significant peak at 30 dpi (p < 0.01), upon which 
levels began to wane (Figure  1B); however, there appeared to 
be a boosting effect upon challenge at 35 dpi. In the PRRSV-1 
SU1-Bel-infected group, Olot/91 neutralizing Abs were not 
measurable until after the challenge (42 dpi, Figure 1B). SU1-Bel 
neutralizing Abs were not detected in the sera of animals from 
either infected group (data not shown). Assessment of PRRSV-
specific T cell IFN-γ responses was conducted by flow cytometry 
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following ex vivo stimulation of PBMC with the homologous 
virus. Both groups showed a higher magnitude of IFN-γ express-
ing CD4 (CD4+CD8αlow) T cells than CD8 (CD4−CD8αhigh) T cells 
in response to homologous virus stimulation (Figures 1C,D). The 
Olot/91 group showed an increase in PRRSV-stimulated CD4 T 
cell responses from 21 dpi that were statistically significant from 
mock stimulation on 35 dpi and onward (p < 0.05). The SU1-Bel 
group displayed a higher overall magnitude of PRRSV-specific 
CD4 T cell responses, which were statistically significant from 
mock stimulation on 14 dpi and onward with a peak at 21 dpi 
(p <  0.05). PRRSV-specific CD8 T cell IFN-γ responses were 
observed at a much lower frequency compared to CD4 T cell 
responses. CD8 T cell responses were statistically significant 
compared to mock stimulation in the Olot/91 group on 14 dpi 
and from 30 dpi onward, and there were no statistically significant 
increases in PRRSV-specific CD8 T cell responses in the SU1-Bel 
group. No significant IFN-γ responses were detected CD4+CD8α− 
or CD4−CD8α−/low T cell populations (data not shown).
screening of PrrsV-1 Proteome-Wide 
synthetic Peptide library to identify T cell 
antigens
Peptides were pooled to represent PRRSV-1 proteins and recog-
nition by PBMC assessed using an ex vivo IFN-γ ELISpot assay 
21 days after infection (21 dpi) and 16 days after challenge (51 dpi) 
for both the Olot/91 (Figure 2) and SU1-Bel (Figure 3) groups. 
Similar to our earlier study (27), animals mounted responses to 
a range of PRRSV-1 peptide pools. Pigs in the Olot/91 group 
displayed a greater magnitude of response to peptide pools after 
challenge as well as an increase in the number of pigs mounting 
significant responses to particular pools. The most prominent 
response in terms of the proportion of animals mounting a 
significant response was to the M peptide pool, to which all pigs 
showed a statistically significant response at both time points 
(Figure 2). Peptides representing NSP5 also induced significant 
IFN-γ responses, with 4/5 of pigs responding after infection and 
all pigs responding after challenge. Similar to the Olot/91 group, 
the SU1-Bel group also displayed greater T cell IFN-γ responses 
after challenge (Figure  3). The most striking observation was 
the magnitude of the IFN-γ response to the NSP5 peptide pool 
after challenge in 4/5 animals compared to 2/5 after infection. 
Interestingly, pig 88 did not mount a significant response to NSP5 
after infection but the response after challenge had the greatest 
magnitude of all. Significant responses were also observed against 
the M peptide pool with 4/5 responders after infection and 5/5 
responders after challenge. Thus, in both groups, M and NSP5 
peptide pools were the most dominant antigens in terms of fre-
quency of responder animals and the magnitude of the response 
and were selected for further study.
characterization of the Kinetics and 
Phenotype of PrrsV-1 M- and  
nsP5-specific T cell responses
The T cell responses to peptide pools representing M and NSP5 
proteins were measured longitudinally over the time course of 
infection and challenge using previously cryopreserved PBMC 
and flow cytometry. The IFN-γ response to the M protein differed 
significantly between individual animals both in terms of mag-
nitude and phenotype (Figure 4). The frequencies of M-specific 
IFN-γ secreting CD8 T cells observed in pigs 86, 87, and 00, all 
infected with Olot/91, were of an order of magnitude greater than 
the other animals and are therefore presented with a different 
y-axis scaling. Compared to unstimulated controls, these three 
animals all mounted a significant CD8 T cell response to the M 
peptide pool, as did the remaining animals in the Olot/91 group, 
pigs 71 and 70 (p < 0.01). Pigs 70 and 71 also mounted a CD4 T 
cell response, which was greater in magnitude than their CD8 T 
cell response (p < 0.01). Within the SU1-Bel group, pigs 72 and 88 
also mounted a significant CD4 (CD4+CD8αlow) T cell response 
to the M peptide pool (p <  0.01). Pigs 73, 89, and 01 did not 
mount a significant response to the M peptides at any time point 
tested with the preserved cells. The earliest statistically significant 
T cell response was seen on 7 dpi in pigs 71 (CD8) and 72 (CD4) 
and significant responses continued until 51  dpi (pigs 70 and 
72 – CD4; pigs 87 and 00 – CD8).
As with the response to the M peptides, there was a variation 
in the magnitude and kinetics of T cell IFN-γ responses to the 
NSP5 peptides between individual animals (Figure 4). Compared 
to M-specific responses, the IFN-γ response to NSP5 was in the 
majority of animals greater and in all cases exclusively from CD8 
T cells. As was seen in the IFN-γ ELISpot assay data (Figures 2 
and 3), all pigs responded to NSP5 with the exception of pig 89 
(p <  0.01). Pigs 70, 71, and 86 (all infected with Olot/91) pre-
sented with exceptionally strong responses to NSP5, peaking at 
a frequency of >10% CD8 T cells expressing IFN-γ in response 
to NSP5 stimulation, and therefore, these animals are shown 
with a separate y-axis scaling. Responses tended to peak between 
days 21 and 35 after infection, and there was no clear evidence of 
boosting after challenge.
characterization of the activation/Memory 
Phenotype and Polyfunctionality of 
PrrsV-1 M- and nsP5-specific T cell 
responses
Peripheral blood mononuclear cells previously isolated from 
selected responder pigs from each infection group on 30 dpi were 
stimulated with either M or NSP5 peptide pools to determine 
the expression of markers of activation, memory, or functional-
ity on antigen-specific T cells. Stimulated cells were stained to 
additionally assess the expression of CD44, CD62L, CD25, CD27, 
the cytotoxic degranulation maker CD107a, and TNF-α by IFN-
γ+ CD4 and CD8 T cells (Figure 5). The results showed that the 
majority of IFN-γ+ NSP5-specific CD8 T cells and M-specific 
CD4 T cells expressed high levels of CD44 (p < 0.01), low levels 
of CD62L (p < 0.01), and lacked expression of CD25 (p < 0.01). 
IFN-γ expressing M-specific CD4 and NSP5-specific CD8 T cells 
displayed variable levels of CD27, but the greatest number were 
classified as CD27low (p < 0.01) followed by CD27high (p < 0.05). 
Almost all IFN-γ+ NSP5-specific CD8 T cells and surprisingly 
the majority of M-specific CD4 T cells had mobilized CD107a 
to their surface (p < 0.01). The majority of antigen-specific cells 
FigUre 2 | recognition of PrrsV-1 proteins by T cells from pigs experimentally infected with the Olot/91 strain. PBMC from pigs experimentally 
infected with PRRSV-1 Olot/91 (n = 5) were isolated on day 21 and day 51 postinfection (16 days post-challenge), and stimulated in vitro with synthetic peptides 
pooled to represent 19 PRRSV-1 proteins. IFN-γ secreting cells were enumerated by ELISpot assay. Data are presented as IFN-γ spot forming cells 
(SFC)/5 × 105 PBMC (triplicate cultures) for each animal and error bars show the SEM. Values for each peptide pool-stimulated condition were compared to the 
corresponding unstimulated (medium) control using a one-way ANOVA followed by a Dunnett’s multiple comparison test; ***p < 0.001, **p < 0.01, and *p < 0.05.
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FigUre 3 | recognition of PrrsV-1 proteins by T cells from pigs experimentally infected with the sU1-Bel strain. PBMC from pigs experimentally 
infected with PRRSV-1 SU1-Bel (n = 5) were isolated on day 21 and day 51 postinfection (16 days post-challenge), and stimulated in vitro with synthetic peptides 
pooled to represent 19 PRRSV-1 proteins. IFN-γ secreting cells were enumerated by ELISpot assay. Data are presented as IFN-γ spot forming cells 
(SFC)/5 × 105 PBMC (triplicate cultures) for each animal and error bars show the SEM. Values for each peptide pool-stimulated condition were compared to the 
corresponding unstimulated (medium) control using a one-way ANOVA followed by a Dunnett’s multiple comparison test; ***p < 0.001, **p < 0.01, and *p < 0.05.
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FigUre 4 | assessment of nsP5- and M-specific iFn–γ T cell responses over the course of infection and challenge with PrrsV-1 Olot/91 and 
sU1-Bel strains. Previously cryopreserved PBMC were stimulated ex vivo with synthetic peptide pools representing M or NSP5 protein or left unstimulated. IFN-γ 
expression by CD4+CD8αlow (CD4; open symbols) and CD4−CD8αhigh (CD8; closed symbols) T cells from unstimulated (square symbols) or peptide pool-stimulated 
cultures (circle symbols) was assessed by flow cytometry. The mean % of IFN-γ+ T cells from duplicate cultures are presented for each animal and error bars show 
the SEM. Data from peptide pool-stimulated cultures were compared against the corresponding unstimulated culture using a two-way ANOVA followed by a Tukey’s 
multiple comparison test.
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FigUre 5 | assessment of the phenotype and polyfunctionality of PrrsV-1 nsP5-specific cD8 T cells.  
(Continued)
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Previously cryopreserved PBMC from identified T cell responder pigs on day 30 postinfection were stimulated with synthetic peptide pools representing M or NSP5 
proteins or left unstimulated. The expression of CD44, CD62L, CD25, CD27, surface CD107a, and TNF-α by IFN-γ+ CD4 T cells in response to M peptides and CD8 
T cells in response to NSP5 peptides were assessed by flow cytometry as shown by representative dot plots. The mean % of unstimulated-corrected data from 
duplicate cultures are presented for individual animals and error bars show the SEM.
FigUre 5 | continued
TaBle 1 | Porcine Mhc (sla) class i and ii low-resolution (lr) haplotypes of PrrsV-infected pigs and T cell reactivity against identified antigenic 
peptides.
group Pig sla-i lr haplotype cD8 T cell antigenic peptide sla-ii lr haplotype cD4 T cell antigenic peptide
Olot/91 70 22.0/35.0 NSP513–27 NSP5156–167 0.01/0.15b M29–43
71 22.0/35.0 NSP513–27 NSP5156–167 0.01/0.15b M29–43
86 35.0/38.0 NSP5149–159 0.11/0.15b
87 35.0/38.0 NSP5149–159 0.11/0.15b
00 43.0/NDa NSP5149–159 0.01/0.02
SU1-Bel 72 22.0/35.0 NSP5156–167 0.01/0.15b M29–43
73 22.0/62.0 NSP5156–167 0.01/0.11
88 22.0/35.0 NSP513–27 NSP5156–167 0.01/0.15b M29–43
89 35.0/38.0 0.11/0.15b
01 04.0/22.0 NSP5156–167 0.01/0.02
aND, not determined.
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coexpressed IFN-γ and TNF-α (p < 0.01), with the absence of a 
significant proportion of antigen-specific cells expressing TNF-α 
alone (data not shown).
Mapping of responses on PrrsV-1 M and 
nsP5 Proteins and assessment of the 
effect of antigenic Polymorphism and 
Mhc haplotype expression
Identification of the antigenic peptide targets of M- and NSP5-
specific T cell responses was assessed using a two-way matrix 
pooling system to screen the individual 15mers. Putative 
antigenic peptides were identified from the matrix pool screens 
then screened individually (Data Sheet S1 in Supplementary 
Material). Pigs 70 and 71, from the Olot/91 group, and pigs 72 
and 88, from the SU1-Bel group, presented significant CD4 T 
cell responses to M peptide #8 (M29–43; MIYALKVSRGRLLGL) 
and pig 71 also showed reactivity to the overlapping peptide 
#9 (M33–47; LKVSRGRLLGLLHIL). CD8 T cells from pigs 70, 
71 (both Olot/91 group), and 88 (SU1-Bel group) showed a 
statistically significant response to NSP5 peptide #4 (NSP513–27; 
FLLWRMMGHAWTPIV). In addition, these pigs, as well as pigs 
72, 73, and 01 (all SU1-Bel group), showed a significant response to 
overlapping NSP5 peptides #39 and #40 (NSP5153–167 and NSP5156–
170) with the consensus sequence NSP5156–167 (DGSFSSAFFLRY). 
Pigs 86, 87, and 00 responded to a second set of overlapping 
NSP5 peptides #37 and #38 (NSP5145–159 and NSP5149–163) with the 
consensus sequence NSP5149–159 (LHNMLVGDGSF). A summary 
of the identified antigenic regions are shown in Table 1.
Animals were MHC typed to assess whether peptide-specific 
T cell responses could be attributed to specific MHC class I and II 
haplotypes (Table 1). With regards to MHC class I, pigs 70, 71, 72, 
and 88 were haploidentical heterozygotes, expressing haplotypes 
Lr-22.0 and 35.0. Pigs 86, 87, and 89 also shared the haplotype 
Lr-35.0 with these animals, as well as haplotype Lr-38.0 between 
themselves. This may suggest that the antigenic region NSP5156–167 
recognized by pigs 70, 71, 72, 73, 88, and 01 was restricted by 
the SLA-I haplotype Lr-22.0. The antigenic region NSP5145–159 
appeared to be restricted by more than one haplotype since pig 00 
did not share either of its haplotypes with any of the other respond-
ers. It could be speculated that this region is potentially restricted 
by Lr-38.0 (taking into account the non-responding pig 89) and 
Lr-35.0 in the absence of Lr-22.0. The antigenic region NSP513–27 
could similarly be restricted by multiple haplotypes. The pigs that 
responded to the CD4 T cell antigenic peptide M29–43 (pigs 70, 71, 
72, and 88) were haploidentical, sharing both SLA-II haplotypes 
Lr-0.01 and 0.15b, this combination appearing exclusively in these 
animals suggesting restriction by one of these two haplotypes.
The level of amino acid sequence conservation of antigenic 
peptides both within genotype 1 PRRSV strains and between 
genotypes was investigated to further evaluate the identified 
antigens. The complete predicted amino acid sequences of M 
from 64 PRRSV-1 and 31 PRRSV-2 strains and NSP5 from 19 
PRRSV-1 and 36 PRRSV-2 strains were aligned and the number of 
different amino acid variants at each residue plotted (Figure 6A). 
The results showed that both proteins were well conserved with 
either no or only a single amino acid substitution being observed 
for the majority of residues. There was no evidence of regions of 
hypervariability in either of the antigens. The predicted amino 
acid sequences of identified antigenic regions, M29–43, NSP513–27, 
and NSP5149–167, were compared among the panel of 19 PRRSV-1 
strains, for which both M and NSP5 sequence data were available, 
and a consensus sequence based on available PRRSV-2 strains 
(Figure  6B). All antigenic sequences were conserved between 
PRRSV-1 Olot/91 and the SU1-Bel strain, which explained the 
observed conservation in the specificity of responses across the 
infection groups. Identified variant sequences were synthesized 
and tested for their ability to induce T cell IFN-γ responses 
from representative pigs 86 and 71 (Figure 6C). The CD4 T cell 
antigenic region of M was well conserved with only one variant, 
FigUre 6 | assessment of the conservation of identified T cell antigens M and nsP5 among PrrsV strains and assessment of T cell reactivity 
against variant peptides. The complete predicted amino acid sequences of M (from 64 PRRSV-1 and 31 PRRSV-2 strains) and NSP5 (from 19 PRRSV-1 and 36 
PRRSV-2 strains) were aligned and the number of different amino acid variants at each residue plotted (a). The predicted amino acid sequences of identified 
antigenic regions, M29-43, NSP513-27, and NSP5149-167, were compared among the panel of 19 PRRSV-1 strains, for which both M and NSP5 sequence data were 
available, and a consensus sequence based on available PRRSV-2 strains (B). Based on the observed amino acid substitutions, variant peptides were used to 
stimulate PBMC from pigs 71 and 86 (c). IFN-γ expression by CD4 T cells to M29-43 (pig 71) and CD8 T cells to NSP513-27 (pig 71), NSP5145-159 (pig 86), and 
NSP5153-170 (pig 71) peptides were assessed by flow cytometry. The mean% of unstimulated (medium) and peptide stimulated data from duplicate cultures are 
presented and error bars show the SEM. Values were compared to the unstimulated control using a one-way ANOVA followed by a Dunnett’s multiple comparison 
test; ***p < 0.001, **p < 0.01, and *p < 0.05.
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a related substitution of a histidine for an arginine at position 
37, which still stimulated a CD4 T cell response (although not 
deemed statistically significant). The NSP513–27 antigenic region 
had four potential amino acid substitutions, all but one of which 
still induced a statistically significant CD8 T cell IFN-γ response. 
The individual 15mers that made up NSP5145–159 possessed substi-
tutions at four positions; however, all but one of the six variants 
induced a statistically significant IFN-γ response (although four of 
these lay outside the consensus sequence and therefore prob-
ably had no effect on the antigenic region). While there were 
only two amino acid substitutions in the NSP5153–170 region, 
these removed the peptides ability to stimulate a CD8 T cell 
IFN-γ response.
DiscUssiOn
IFN-γ secreting T cell responses appear important, if not essen-
tial, for resolution of PRRSV infection (15). The present study 
showed, at least in the context of PRRSV-1 SU1-Bel infection, that 
viremia was cleared and protection against secondary infection 
occurred in the absence of measurable nAbs but not T cell IFN-γ 
responses, suggesting the latter response could be sufficient to 
protect against PRRSV infection. These data support our earlier 
study of the immune responses induced by SU1-Bel (5). The abil-
ity of PRRSV infection to prime both CD4 and CD8 T cells was 
in accordance with the literature, also agreeing with the stronger 
observed CD4 T cell response following in  vitro stimulation 
with PRRSV (43). However, comparison with the frequencies of 
PRRSV peptide-specific CD4 and CD8 T cells revealed that the 
assessment of PRRSV-specific CD8 T cell responses by stimula-
tion with live virus greatly underestimated the true response. It 
may be speculated that a low level of productive PRRSV infection 
occurs within PBMC, and this limits the availability of NSPs and/
or trafficking of PRRSV peptides into the “direct” or cytosolic 
MHC class I processing and presentation pathway resulting in 
suboptimal CD8 T cell stimulation.
Strong T cell responses were directed against the M and NSP5 
proteins in pigs infected with both Olot/91 and SU1-Bel strains. 
These proteins have been identified previously as bearing T cell 
epitopes (27, 32, 35, 37), but the phenotype of the responding T 
cells had, in most instances, not been defined. Indeed, the identity 
of NSP5 peptides that induce IFN-γ has only been reported in one 
other study to date, and none of the antigenic peptides matched 
those identified here (37). A T cell antigenic region of the M 
protein, “M6,” previously identified from a highly pathogenic 
PRRSV-2 strain (35) shows a significant overlap with the CD4 T 
cell antigenic peptide M29–43 identified here. The epitopes on each 
antigen that the individual pigs responded to appear dependent 
on the MHC haplotypes of the pigs rather than the virus strain 
they were infected with and certain antigenic regions could 
potentially be attributed to, in some instances, multiple haplo-
types. In our previous evaluation of T cell responses using the 
PRRSV-1 peptide library (27), we observed significant M-specific 
responses from animals infected with Olot/91, SU1-Bel, and 
Lelystad strains, whereas NSP5-specific responses were only 
detectable within the SU1-Bel infected group, suggesting that the 
combination of infecting strain and MHC haplotype influences 
the antigen-specificity of T cell responses. The antigenic peptides 
in the present study were highly conserved among PRRSV-1 
strains and in some cases with PRRSV-2 strains. Pigs could still 
respond to antigenic peptides with certain amino acid substitu-
tions identified in divergent strains, for example in NSP5153–170, 
which is encouraging for vaccine applications when considering 
the diversity of PRRSV strains in the field.
The M protein was recognized by both memory CD4 
(CD4+CD8αlow) and CD8 (CD4−CD8high) T cells (41, 44), 
whereas the NSP5 was the target of a CD8 T cell response. A 
cytotoxic CD8 T cell response is important for the control of 
viral replication, especially in chronic or persistent viral infec-
tions, but CD4 T cells also play a crucial role in the induction of 
CD8 T cell responses. According to the current paradigm, two 
distinct subsets of memory T cell exist, effector memory (TEM) 
and central memory (TCM) (45). These can be distinguished 
by the lymph node homing markers CD62L and CCR7, with 
CD62L+CCR7+ and CD62L−CCR7− cells representing the TCM 
and TEM, respectively (46). TEM cells are highly enriched at 
tissue effector sites including the lungs and mucosae, are poly-
functional expressing multiple effector cytokines (TNF-α and 
IFN-γ), and with relatively immediate cytotoxic potential. TCM 
are instead primarily localized to central lymphoid tissue and 
are also relatively delayed in their effector response requiring 
de novo exposure to the invading pathogen before acquiring 
full effector function (45). Phenotyping of the IFN-γ expressing 
responder CD4 and CD8 T cells showed that the majority of 
cells expressed high levels of CD44, low levels of CD62L and 
CD27, lacked expression of CD25−, displayed a marker of 
cytotoxic degranulation (CD107a), and coexpressed TNF-α. 
Based on the studies in humans and mice, the high expression 
of cell adhesion molecule CD44 and low expression of CD62L 
putatively identifies these responding T cells as effector (TEFF) 
or TEM cells. The majority of IFN-γ+ T cells expressed low levels 
of CD27, which may classify them as TEM cells if orthologous to 
the human system (47, 48). The lack of coexpression of CD25 
and IFN-γ on M- and NSP5-specific T cells further suggested a 
TEM phenotype. These results make a further contribution to the 
growing body of data delineating porcine memory T cell subsets 
(44). Dual or polyfunctional T cells as defined by the simultane-
ous secretion of IFN-γ and TNF-α have been correlated with the 
enhanced quality and robustness of the T cell response (49) and 
the ability of the M and NSP5 proteins to stimulate these dual 
cytokine expressing cells further supports the use of these two 
antigens in future vaccine development. CD107a mobilization 
is considered a marker for cytotoxic degranulation (50) and 
the majority of the M- and NSP5-specific T cells were shown to 
express both IFN-γ and CD107a. CD107a expression has been 
described on antigen-specific porcine CD8 T cells previously 
(39). Its expression on porcine CD4 T cells was unexpected 
although CD4+CD8+ T cell cytotoxic activity has been described 
in the context of African swine fever infection (51), as well as in 
humans and mice (52).
In conclusion, this study has used an unbiased strategy to iden-
tify PRRSV-1 antigens. Our characterization of the PRRSV-1 M 
and NSP5 antigens and the specific polyfunctional TEM responses 
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strongly suggest their vaccine potential and provide a solid basis 
for their evaluation in efforts to develop a subunit-based next-
generation PRRSV vaccine.
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